50. 皮膚筋炎/多発性筋炎 Dermatomyositis Clinical trials / Disease details


臨床試験数 : 194 薬物数 : 244 - (DrugBank : 89) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 151

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000036709
2020-10-012020-08-24Study on early warning of rapid progressive interstitial lung disease in dermatomyositisStudy on early warning of rapid progressive interstitial lung disease in dermatomyositis DermatomyositisGroup 1:Glucocorticoid + cyclophosphamide + cyclosporin;Group 2:Glucocorticoid + cyclophosphamide + Tofacitinib;Zhongshan Hospital of Fudan UniversityNULLPending1860BothGroup 1:15;Group 2:15;N/AChina
2NCT04613219
(ClinicalTrials.gov)
October 1, 202015/9/2020Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung DiseaseCorrelation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung DiseaseClinically Amyopathic Dermatomyisitis(CAMD)Drug: Tofacitinib 5 MG [Xeljanz]Jing LiangNULLRecruiting18 Years80 YearsAll80China
3ChiCTR1800016629
2017-07-012018-06-14An observation of tofacitinib in patients of MDA5+ clinically amyopathic dermatomyositis with interstitial lung diseaseAn observation of tofacitinib in patients of MDA5+ clinically amyopathic dermatomyositis with interstitial lung disease dermatomyositisstudy group:tofacitinib;control group:glucocorticoids+immunosuppressant;Ren Ji Hospital South Campus, Shanghai Jiaotong University School of MedicineNULLRecruiting1880Bothstudy group:15;control group:35;China
4NCT03002649
(ClinicalTrials.gov)
January 201720/12/2016Study of Tofacitinib in Refractory DermatomyositisStudy of Tofacitinib in Refractory Dermatomyositis (STIR): Proof of Concept, Open-Label Study of 10 PatientsDermatomyositisDrug: TofacitinibJohns Hopkins UniversityPfizerCompleted18 YearsN/AAll10Phase 1United States